QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

This study is testing a combination of immunotherapy (QL1706) with chemotherapy, with or without the drug bevacizumab, as a first-line treatment for women with triple-negative breast cancer (TNBC) that has spread or cannot be surgically removed. TNBC is an aggressive form of breast cancer that lacks the hormone and HER2 receptors. **You may be eligible if...** - You are a woman between 18 and 70 years old - You have been diagnosed with triple-negative breast cancer (ER-, PR-, HER2-negative) confirmed by biopsy - Your cancer has spread or come back and you have not had prior systemic treatment for advanced disease - You have at least one measurable tumor site **You may NOT be eligible if...** - Your breast cancer is not triple-negative - You have already received treatment for metastatic or locally advanced disease (except prior adjuvant/neoadjuvant therapy given long enough ago) - You have significant health conditions that prevent participation Talk to your doctor to see if this trial is right for you.